Template:Erysipelas antibiotics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
''Coverage for [[S. pyogenes]]'' | ''Coverage for [[S. pyogenes]]'' | ||
*[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR''' | *[[Penicillin G]] 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy<ref name="Linke">Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.</ref>) '''OR''' | ||
*[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR''' | *[[Clindamycin]] 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) '''OR''' | ||
| Line 7: | Line 6: | ||
*[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR''' | *[[Levofloxacin]] 500mg PO/IV daily x 10 days '''OR''' | ||
*[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy) | *[[Augmentin]] 500mg PO BID x 10 days (generally reserved for failure of first line therapy) | ||
Bullous Erysipela or [[MRSA]] suspected: [[trimethoprim-sulfamethoxazole]], [[clindamycin]], [[doxycycline]], or [[minocycline]] | |||
Latest revision as of 13:38, 23 November 2017
Coverage for S. pyogenes
- Penicillin G 300K U/d IM for <30 kg, 600K to 1 million U/d IM for >30 kg (first line therapy[1]) OR
- Clindamycin 450mg (5mg/kg) PO q8hrs x 10 days (if PCN allergic) OR
- Cephalexin 500mg (6.25mg/kg) PO q6hrs x 10 days OR
- Ceftriaxone 1g (50mg/kg) IV once daily x 10 days OR
- Levofloxacin 500mg PO/IV daily x 10 days OR
- Augmentin 500mg PO BID x 10 days (generally reserved for failure of first line therapy)
Bullous Erysipela or MRSA suspected: trimethoprim-sulfamethoxazole, clindamycin, doxycycline, or minocycline
- ↑ Linke M, Booken N. Risk factors associated with a reduced response in the treatment of erysipelas. J Dtsch Dermatol Ges. 2015 Mar;13(3):217-25.